Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment.

• DOI: 10.1200/jco.2014.32.15_suppl.e15160
• Publication Date: 2019-01-03T22:31:37Z
• Authors: Emilio Bajetta; Laura Catena; Sara Pusceddu; Francesca Spada; Nicola Fazio; Giusi Blanco; Sergio Ricci; Michele Aieta; Francesca Pucci; Monica Valente; Nadia Bianco; Italo Sarno; Giandomenico Di M...
• Keywords: Everolimus; Clinical endpoint; Progression-free survival

e15160 Background: We previously presented data about this phase II study showing that the combination of Everolimus and octreotide LAR in first line setting for advanced NETs, is an active a safe treatment. At medium follow-up 277 days, median time to progression (TTP) overall survival (OS) have not been reached (ASCO 2013 Abs. 4136). Methods: performed 2, multicenter trial using Simon two-stage minmax design. Patients with well differentiated, untreated NETs gastroenteropancreatic (GEP) tract lung, received ocreotide 30mg every 28 days everolimus 10mg per day continuously. The primary end point was objective response rate (ORR). Currently we perform further analysis OS TTP at 17.8 months. Results: A total 50 patients (58% males) were enrolled. age 60.5 years (range 25-76). Primary tumor site pancreas 14 (28%), unknown lung 11 (22%), ileum 9 (18%), jejunum 1 duodenum patients. One patient add complete response, 16% partial 72% achieved stable disease. months 33.2 (95% CI 19-41.7). has reached. 13 are still benefiting from treatment (11 GEP 2 typical carcinoid lung). Conclusions: shown be tolerated NETs. current showed futher prolungation suggesting possible long term benefit Aknowledgments:Italian Trials Medical Oncology (I.T.M.O.) Group, Giacinto Facchetti Foundation Novartis.